← The Wire
DHRNYSE
DANAHER CORP /DE/
Industrial Instruments For Measurement, Display, and Control · DE · CIK 313616
Danaher develops and commercializes innovative products and services, particularly in healthcare, to meet customer needs and maintain market leadership
red 8-K · 90d🔥 High media attention
$127.47B
Market cap
$192.78
Last close
-1.7%
1D
+8.2%
5D
3.5M
Volume
Price · last 39 sessions+10.8%
May 4L $161.91 · H $196.19Jun 29
149
Total filings
Jun 16, 2026
Last filing
12/31
Fiscal year end
11-K11-KJun 16, 20268-KNew Debt / Obligation · Company UpdateJun 3, 20268-KExecutive Change · Shareholder VoteMay 7, 20268-KMaterial Agreement · Company UpdateApr 29, 2026424B5424B5Apr 23, 2026424B5424B5Apr 22, 20268-KResults of OperationsApr 21, 202610-Q10-QApr 21, 20268-KMaterial Agreement · New Debt / ObligationApr 17, 2026DEFA14ADEFA14AMar 25, 2026DEF 14ADEF 14AMar 25, 202610-K10-KFeb 24, 20268-KCompany UpdateFeb 17, 20268-KExecutive ChangeFeb 10, 20268-KResults of OperationsJan 28, 20268-KResults of OperationsJan 12, 20268-KExecutive ChangeNov 6, 202510-Q10-QOct 21, 20258-KResults of OperationsOct 21, 20258-KBylaw Amendment · Company UpdateSep 10, 20258-KExecutive ChangeJul 31, 20258-KExecutive ChangeJul 24, 202510-Q10-QJul 22, 20258-KResults of OperationsJul 22, 202511-K11-KJun 17, 20258-KShareholder VoteMay 8, 20258-KResults of OperationsApr 22, 202510-Q10-QApr 22, 2025DEFA14ADEFA14AMar 26, 2025DEF 14ADEF 14AMar 26, 20258-KExecutive ChangeFeb 20, 202510-K10-KFeb 20, 20258-KResults of OperationsJan 29, 20258-KResults of OperationsJan 13, 20258-KExecutive ChangeDec 11, 20248-KResults of OperationsOct 22, 202410-Q10-QOct 22, 20248-KResults of OperationsJul 23, 202410-Q10-QJul 23, 20248-KExecutive ChangeJun 20, 202411-K11-KJun 7, 20248-KShareholder VoteMay 9, 20248-KResults of OperationsApr 23, 202410-Q10-QApr 23, 2024DEFA14ADANAHER CORP - DEFA14AMar 27, 2024DEF 14ADANAHER CORP - DEF 14AMar 27, 202410-K10-KFeb 21, 20248-KExecutive ChangeFeb 14, 20248-KResults of OperationsJan 30, 20248-KResults of OperationsJan 8, 20248-KResults of OperationsOct 24, 202310-Q10-QOct 24, 20238-KExecutive Change · Material AgreementOct 2, 20238-KMaterial AgreementSep 19, 20238-KCompany UpdateSep 12, 20238-KMaterial Agreement · New Debt / ObligationAug 31, 20238-KCompany UpdateAug 31, 20238-KMaterial Agreement · New Debt / ObligationAug 15, 20238-KResults of OperationsJul 25, 202310-Q10-QJul 25, 202311-K11-KJun 21, 20238-KResults of Operations · Shareholder VoteMay 11, 20238-KResults of OperationsApr 25, 202310-Q10-QApr 25, 2023DEFA14ADANAHER CORP - DEFA14AMar 29, 2023DEF 14ADANAHER CORP - DEF 14AMar 29, 202310-K10-KFeb 22, 20238-KResults of OperationsJan 24, 20238-KReg FD DisclosureJan 18, 20238-KResults of OperationsJan 9, 20238-KBylaw AmendmentDec 7, 20228-KResults of OperationsOct 20, 202210-Q10-QOct 20, 20228-KResults of OperationsJul 21, 202210-Q10-QJul 21, 20228-KExecutive ChangeJun 29, 202211-K11-KJun 6, 202211-K11-KJun 6, 20228-KShareholder VoteMay 12, 20228-KResults of OperationsApr 21, 2022
Insider Activity
In the 90 days to Feb 19, 2026: 2 sold $9.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 19, 2026 | Milosevich Gregory MExecutive Vice President | Sell | 1,320 | $208.01 | $275K |
| Nov 25, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 35,899 | $230.27 | $8.3M |
| Nov 25, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 4,726 | $231.19 | $1.1M |
| Nov 18, 2025 | List TeriDirector | Sell | 3,298 | $226.50 | $747K |
| Nov 12, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 254,553 | $218.27 | $55.6M |
| Nov 12, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 133,233 | $219.43 | $29.2M |
| Nov 12, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 25,855 | $217.64 | $5.6M |
| Nov 12, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 23,359 | $220.15 | $5.1M |
| Nov 12, 2025 | Ellis Brian WSenior Vice President - GC | Sell | 14,667 | $219.23 | $3.2M |
| Nov 12, 2025 | Ellis Brian WSenior Vice President - GC | Sell | 7,109 | $219.21 | $1.6M |
| Nov 11, 2025 | Mcgrew MatthewEVP & Chief Financial Officer | Sell | 16,172 | $214.62 | $3.5M |
| Nov 10, 2025 | Couchara GeorgeannSVP, Human Resources | Sell | 4,176 | $210.44 | $879K |
| Nov 10, 2025 | Couchara GeorgeannSVP, Human Resources | Sell | 998 | $210.31 | $210K |
| Oct 31, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 308,423 | $215.67 | $66.5M |
| Oct 31, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 223,449 | $216.26 | $48.3M |
| Oct 31, 2025 | Rales Mitchell PChairman of Exec. Committee | Sell | 68,128 | $217.17 | $14.8M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
What Changed
Risk factors · Feb 20, 2025 → Feb 24, 202635 added · 37 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.
Newly disclosed
- For example, incorporating confidential information into AI systems may result in the loss of intellectual property or attorney-client privilege protections, and our use of AI technologies to develop products or services may adversely affect our intellectual property rights or violate third-party intellectual property rights.
- Sales in 2025 for this segment by geographic destination and by revenue type (as a percentage of total 2025 sales) were: Danaher established the Biotechnology segment through the acquisition of Pall in 2015 and expanded the business through the acquisition of Cytiva in 2020.
- The development, adoption, and use of AI technologies are still in their early stages and ineffective, inadequate or premature AI development or deployment practices could result in unintended consequences such as competitive harm, regulatory penalties, legal liability or brand or reputational harm.
- Sales in 2025 by geographic destination (geographic destination refers to the geographic area where the final sale to the Company’s unaffiliated customer is made) and by revenue type (revenue type refers to categorizing the Company’s products between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis) as a percentage of total 2025 sales were: Sales in North America includes 41% in the United States.
- Incorporating AI into our business operations presents new risks relating to intellectual property, disclosure of confidential data, data protection, data privacy and cybersecurity.
- We are in the early stages of incorporating AI, including machine learning technologies, into our business activities and our product and service offerings.
- Promising acquisitions and investments, such as our pending acquisition of Masimo Corporation
- Typical users include research, scientific, medical and surgical professionals as well as quality assurance and quality control technicians operating in pharmaceutical and biotechnology companies, contract development and manufacturing organizations (“CDMO”), clinical research organization universities, medical schools, surgical theaters and research institutions and in some cases industrial manufacturers.
- The business provides consumables and services including antibodies and assays to accelerate scientific research, plasmid DNA, RNA, critical nucleic acids and proteins used to develop and manufacture gene and cell therapies, and analytical tools and services to accelerate discovery, clinical applications and manufacturing for therapies across pharmaceutical, biopharmaceutical, diagnostic and emerging biotechnology companies, research institutions and universities.
- The clinical diagnostics businesses provide diagnostic testing instruments, consumables and software that enable laboratories and healthcare professionals to accurately diagnose, monitor and manage a wide range of diseases and health conditions.
- The availability of governmental research funding has been, and may in the future be, adversely affected by policy changes, economic conditions and governmental spending reductions, including the downsizing or reduced funding of certain government agencies. 18 Demand for our products and services is also sensitive to changes in customer order patterns, which may be affected by announced price changes, marketing or promotional programs that may accelerate demand in a particular fiscal period and diminish demand in subsequent periods, new product introductions, the timing of industry trade shows and changes in distributor or customer inventory levels due to distributor or customer management thereof or other factors.
- Over the past several years we have not 19 consummated acquisitions at rates similar to our historical practice and going forward we may not be able to consummate acquisitions at rates similar to our historical practice, which can adversely impact our business.
No longer disclosed
- Danaher established the Biotechnology segment through the acquisition of Pall in 2015, and expanded the business through the acquisition of Cytiva in 2020. 4 The Biotechnology segment consists of the following businesses: Bioprocessing —The bioprocessing business is a leading provider of technologies, consumables, services and solutions that advance, accelerate and integrate the development and manufacture of therapeutics.
- Sales in 2024 by geographic destination (geographic destination refers to the geographic area where the final sale to the Company’s unaffiliated customer is made) as a percentage of total 2024 sales were: North America, 43% (including 42% in the United States);
- The development, adoption, and use of AI technologies are still in their early stages and ineffective or inadequate AI development or deployment practices could result in unintended consequences.
- The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity and privacy and data protection.
- We are in the early stages of incorporating artificial intelligence (“AI”) into our business activities and our product and service offerings.
- Sales in 2024 for this segment by geographic destination (as a percentage of total 2024 sales) were: North America, 33%;
- Sales in 2024 for this segment by geographic destination (as a percentage of total 2024 sales) were: North America, 44%;
- Typical users of these mass spectrometry and related products include molecular biologists, bioanalytical chemists, toxicologists and forensic scientists as well as quality assurance and quality control technicians. 5 Microscopy —The microscopy business is a leading global provider of professional microscopes designed to capture, manipulate and preserve images and enhance the user’s visualization and analysis of microscopic structures.
- Sales in 2024 for this segment by geographic destination (as a percentage of total 2024 sales) were: North America, 50%;
- The business also offers automation systems that reduce manual operation and associated cost and errors from the pre-analytical through post-analytical stages, including sample barcoding/information tracking, centrifugation, aliquoting, storage and conveyance.
- Typical users of the segment’s core lab products include hospitals, physicians’ offices, reference laboratories and pharmaceutical clinical trial laboratories. 6 Molecular Diagnostics —The molecular diagnostics business is a leading provider of biomedical testing instruments, systems, software and related consumables that enable DNA-based testing for organisms and genetic-based diseases.
- The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions.
In the News
🔥 High media attentionCoverage (30d): 15 reputable articles · skews ▲ positive.
MarketWatchDanaher Corp. stock outperforms competitors on strong trading day3d agoMarketWatchDanaher Corp. stock underperforms Thursday when compared to competitors despite daily gains4d agoMarketWatchDanaher Corp. stock outperforms competitors despite losses on the day12d agoMarketWatchDanaher Corp. stock underperforms Thursday when compared to competitors18d agoMarketWatchDanaher Corp. stock underperforms Wednesday when compared to competitors19d agoMarketWatchDanaher Corp. stock underperforms Tuesday when compared to competitors despite daily gains20d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance